In another neoadjuvant randomized clinical trial, the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer (WSG-ADAPT-HER2+) trial (NCT01817452), compared pCR rates of the HER2-directed antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) versus trastuzumab with ET in early HER2+/HR+ breast cancer91. This evidence concerns the gene ERBB2 and breast carcinoma.